To improve overall immunogenicity and activate specific CD8+ T-cell responses through APC activation, a powerful adjuvant system that can attract immune cells to the site of injection, promote cell-mediated trafficking antigens to drain lymph nodes, and trigger APC activation is indispensable for peptide or protein cancer vaccine development [4]. The gene discussed is CD8A; the disease is cancer.